Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.
暂无分享,去创建一个
R. Epstein | M. Campone | I. Bondarenko | P. Munster | P. Fumoleau | E. Leip | S. Brincat | E. Chmielowska | C. Zacharchuk | N. Bardy-Bouxin | K. Turnbull | R. Ward | Y. Hotko